GCP
TERN

GSA Capital Partners’s Terns Pharmaceuticals TERN Stock Holding History

GSA Capital Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,268
Closed -$536K – 2150
2025
Q4 		$536K Buy
+13,268
New +$307K 0.05% 761
2025
Q1 		– Sell
-26,940
Closed -$149K – 2069
2024
Q4 		$149K Buy
+26,940
New +$182K 0.01% 1471

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

GSA Capital Partners's TERN Position: Q1 2026 in Review

GSA Capital Partners sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 13,268 shares — an estimated $536K sold.

GSA Capital Partners first reported a position in TERN in Q4 2024 and held it in 2 quarters. The position peaked at $536K in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • GSA Capital Partners reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 13,268 Terns Pharmaceuticals shares in Q1 2026, an estimated $536K.
  • GSA Capital Partners first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • GSA Capital Partners's Terns Pharmaceuticals position peaked at $536K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.